P-5-P B-6 Conversion Process May Be Interrupted by Metabolic Disorders, Certain Conditions or Drugs

PYRIDOXAL-5-PHOSPHATE 
Each enteric coated tablet contains:
Pyridoxal-5’-Phosphate	20 mg.
100 tablets

B-6 Conversion Process May Be Interrupted by Metabolic Disorders, Certain Conditions or Drugs

Three forms of vitamin B-6 exist in natural foods: pyridoxine, pyridoxal phosphate and pyridoxamine phosphate. The usual form of supplementation is with pyridoxine hydrochloride which, under normal conditions, is converted to the phosphorylated pyridoxal within the cells. When conditions are not normal, due to use of certain drugs or in certain metabolic conditions, the conversion process may be interrupted and a deficiency results.

In humans and other mammals, the phosphorylation enzyme, pyridoxal kinase, is preferentially activated by zinc and/or magnesium. Subnormal activity of this enzyme, low levels of zinc or magnesium, or impaired membrane transport can cause a deficiency of P-5-P.

Observations during clinical treatment of patients who need vitamin B-6 supplementation have shown that when P-5-P is indicated, it is 10 times more effective than pyridoxine HCl.

In addition, patients with cirrhosis show an increase in alkaline phosphatase and degradation of P-5-P. Intestinal absorption of P-5-P is decreased in patients with celiac disease.

The following drugs have been reported to decrease plasma levels and increase metabolic requirements of P-5-P:

Supplementation with Pyridoxal-5’-Phosphate is indicated for patients with amino acid deficiencies and intestinal malabsorption as well as for patients with increased need for vitamin B-6 due to toxicity, infections or metabolic impairments.

Since there are many causes for vitamin B-6 deficiency, patients who do not respond to vitamin B-6 supplementation with pyridoxine HCl may benefit from Pyridoxal-5'- Phosphate supplementation.

Pyridoxal Phosphate Is Necessary For Amino Acid Metabolism and Many Human Metabolic Sequences

P-5-P is one of the active coenzyme forms of vitamin B-6. Pyridoxal phosphate is required in many human metabolic sequences including the following:

One of the main functions of P-5-P is as a coenzyme for transamination steps (transfer of an amino group). Various hyper-aminoacidurias are often found in cases of functional deficiency of pyridoxal phosphate.

Absorption of amino acids through the intestinal mucosa directly involves the pyridoxal phosphate form of vitamin B-6; therefore, when amino acids are supplemented for the reason of measured deficiency, it is good practice to supplement with P-5-P as well.

In addition, it is good practice to support P-5-P with a supplement containing all the B vitamins, including pyridoxine HCl.

WARNING: This information is provided for the health professionals only. This publication and the product contained herein have not been approved or evaluated by the Food and Drug Administration. This publication, and the product contained herein are not intended to diagnose, treat, cure or prevent any disease. The product relates to nutritional support only.

1.Ha, C, Miller, L, Karkvliet, N, “The effect of vitamin B-6 deficiency on cytotoxic immune responses of T-cells, antibodies and natural killer cells in phagocytosis by macrophages”. Cellular Immunology, 85:318-29, 1984.

2.Casciato, D, McAdam, L, Kopple, J, et al, “Immunologic abnormalities in hemodialysis patients: Improvement after pyridoxine therapy”. Nephron 38:9-16, 1984.

3.Hallert, C, Anstrom, J, Walan, A, “Reversal of psycopathology in adult celiac disease with the aid of pyridoxine (vitamin B-6)”, Scand. J. Gastroenterol 18:299-304, 1983.

4.Serfontain, W, De Villiers, L, Ubbink, J, et al, “Vitamin B-6 revisited: Evidence of subclinical deficiencies in various segments of the population and possible consequences thereof”, S Afr Med J, 66:437-41, 1984.

5.Mitchell, D, Wagner, C, Stone, W, et al, “Abnormal regulation of plasma P-5-P in patients with liver disease”, Gastroenterology 71:1043-49, 1976.

6.Henderson, J, Codner, M, Hollins, B, et al, “The fasting B-6 itamer profile and response to pyridoxine load in normal and cirrhotic subjects”. Hepatology, 6(3):464-71, 1986.

7.Merrill, A.H., Henderson, J, Wang, E, et al, “Activities of the hepatic enzymes on Vitamin B-6 metabolism for patients with cirrhosis”. Am J Clin Nutr, 44:461-67, 1986.

8.Serfontain, W, Ubbink, J, Devillers, L, et al, “Plasma P-5-P level as risk index for coronary artery disease”. Atherosclerosis, 55:357-61, 1985.

9.Zamen, S, Tredger, J, Johnson, P, et al, “Vitamin B-6 concentrations in patients with chronic liver disease and hepatocellular carcinoma”, Brit. Med J, 293:175, 1986

10.Chabnor, B, DeVita, V, Livingston, D, et al, “Abnormalities of tryptophan metabolism and plasma pyridoxal phosphate in Hodgkin’s Disease”, N Eng. J Med, 282:838-43, 1970.

11.Potera, C, Rose, D, Brown, R, “Vitamin B-6 deficiency in cancer patients”, Am J Clin Nutr, 30:1877-9, 1977.

12.Crowell, G, Roach, E, “Pyridoxine-dependent seizures”, AFP, 27(3):183-7, 1983

13.Roe, D, “Drug Induced Nutritional Deficiencies”, 2nd ed., AM Publ, Westport, CT, 1985

14.Rumsby, P, shepherd, D, “The effect of drugs on vitamin B-6 function in the rat”, Biochem Pharmacol, 29:3097-3102, 1980.

15.Merrill, AH, Jr., Henderson, JM, “Diseases associated with defects in vitamin B-6 metabolism or utilization”, Ann Rev Nutr, 7:137-58, 1987.

16.Holtz, P, Palm, D, “Pharmacologic Aspects of Vitamin B-6”, Pharmaco Rev, 16:113, 1984.

17.Hemmiga, N, Bhagavan, B, “Drug-Vitamin B-6 Interaction in Nutrition and Drugs”, Winick, M, ed, 1-12, John Wiley and sons, New York, 1983.

18.Kaklem J, “Vitamin B-6 requirement and oral contraceptive use – A concern?”, J Nutr, 116:475-7, 1986.

19.Keniston, R, Cabelion, S, Yarbrough, K, “P-5-P as an antidote for cyanide, spermine, gentamicin and dopamine toxicity. An in vivo rat study”, Toxicology and Applied Pharmacology, 88:433-41, 1987.